Revance Therapeutics Inc. (RVNC) 22.31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Revance Therapeutics Inc. (RVNC) 22.31 $RVNC

TherapeuticsMD Appoints Biopharmaceutical Senior Executives Angus C. Russell and J. Martin Carroll as Independent Directors
Business Wire - Wed Mar 18, 7:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
TXMD: 7.17 (+0.01), SHPG: 253.58 (+3.70), RVNC: 22.31 (-0.58)

4 Stocks Spiking on Big Volume: Arista Networks and More
at The Street - Mon Mar 16, 11:52AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
ANET: 66.27 (+0.40), CTSO: 7.13 (-0.06), RVNC: 22.31 (-0.58), HSIC: 141.11 (+1.14)

Revance Therapeutics' (RVNC) CEO Dan Browne on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:40PM CST

RVNC: 22.31 (-0.58)

Revance reports 4Q loss
Automated Insights - Mon Mar 02, 5:13PM CST
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $14.2 million in its fourth quarter.
RVNC: 22.31 (-0.58)

Revance Therapeutics beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:22PM CST

RVNC: 22.31 (-0.58)

Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook
GlobeNewswire - Mon Mar 02, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today financial results for the fourth quarter and full year ended December 31, 2014.
RVNC: 22.31 (-0.58)

Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
GlobeNewswire - Tue Feb 17, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health Care Conference in Boston.
RVNC: 22.31 (-0.58)

Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that the Company will release fourth quarter and full year 2014 financial results on Monday, March 2, 2015 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
RVNC: 22.31 (-0.58)

Commit To Purchase Revance Therapeutics At $15, Earn 13.2% Annualized Using Options
at The Street - Fri Jan 23, 11:02AM CST
Investors eyeing a purchase of Revance Therapeutics Inc stock, but cautious about paying the going market price of $16.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
RVNC: 22.31 (-0.58)

Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
GlobeNewswire - Mon Jan 12, 6:00AM CST
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications
RVNC: 22.31 (-0.58)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 4:35PM CST

HELE: 79.26 (-0.19), EOPN: 8.59 (unch), RRTS: 25.07 (-0.25), CNAT: 6.31 (-0.15), JNUG: 19.83 (-2.03), RVNC: 22.31 (-0.58), AGI: 6.74 (-0.39), FIVE: 35.27 (-0.01), BARL: 19.19 (unch), SBLK: 3.67 (-0.11)

Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study
GlobeNewswire - Thu Jan 08, 3:06PM CST
RT002 Achieved Median Duration of 7 Months
RVNC: 22.31 (-0.58)

Revance starts Phase 2 trial for aesthetic treatment for frown lines
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:40AM CST

RVNC: 22.31 (-0.58)

Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002
GlobeNewswire - Mon Jan 05, 6:23AM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced initiation of the BELMONT trial, a Phase 2, Randomized, Double-Blind, DosE Ranging, Active and PLacebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration Of Effect of RT002, a BotuliNum Toxin Type A for Injection, to Treat Glabellar Lines, more commonly known as frown lines. RT002, incorporating Revance's patented TransMTS(R) delivery technology, is an investigational product designed to offer more targeted delivery of botulinum toxin to intended treatment sites with reduced spread beyond the site of local injection. Last April, Revance reported the results of a Phase1/2 study which showed median duration of 29.4 weeks, which exceeds the labeled duration of currently marketed botulinum toxin products for the treatment of glabellar lines.
RVNC: 22.31 (-0.58)

Revance Therapeutics Added to NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 363.84 (-0.66), RVNC: 22.31 (-0.58)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), FPRX: 24.07 (-0.85), ZFGN: 39.06 (+0.36), CRIS: 2.88 (+0.09), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.96 (-0.50), ZSPH: 42.50 (+1.08), AMRN: 2.34 (-0.05), OPHT: 52.35 (+1.09), AERI: 34.42 (-0.70), ASPX: 100.79 (+0.09), CNCE: 14.83 (+0.26), ICEL: 16.47 (-0.02), GWPH: 113.04 (-0.05), AUXL: 36.47 (-0.06), RTRX: 24.45 (+0.09), RCPT: 166.76 (-3.37), AAVL: 38.93 (-0.42), AKBA: 8.39 (+0.07), EXPR: 17.33 (+0.04), RARE: 66.96 (+2.74), ZGNX: 1.63 (-0.02), RLYP: 35.39 (-0.54), PETX: 16.15 (+0.01), ENTA: 36.99 (+0.01), RDUS: 41.90 (-0.48), CARA: 12.98 (+0.15), FLML: 15.84 (-0.33), ALIM: 4.92 (-0.09), ANIP: 69.79 (+1.24), ICPT: 280.45 (-8.26), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22), NDAQ: 48.84 (+0.12), FPRX: 24.07 (-0.85), CRIS: 2.88 (+0.09), ZFGN: 39.06 (+0.36), QLTI: 3.75 (-0.04), PCYC: 256.98 (-0.77), PTX: 7.44 (-0.05), CLDN: 13.59 (-2.77), RIGL: 4.24 (+0.07), HPTX: 45.96 (-0.18), AMPH: 15.08 (-0.13), INO: 10.39 (-0.09), VSAR: 18.31 (-0.81), FMI: 48.71 (-0.96), TBPH: 18.41 (+0.18), XLRN: 33.67 (-0.02), MGNX: 33.73 (-0.05), INSM: 23.12 (-0.10), ONTX: 2.48 (-0.05), ALDR: 25.13 (-0.19), SAGE: 59.50 (-2.56), KITE: 57.56 (-1.43), CGEN: 7.10 (+0.01), FOLD: 11.97 (-0.35), KPTI: 32.24 (-0.60)

Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), NKTR: 10.90 (+0.16), AGN: 240.22 (+2.88), IPXL: 49.58 (-0.40), ALDR: 25.13 (-0.19), MRK: 57.69 (+0.03), RVNC: 22.31 (-0.58), POZN: 8.36 (+0.22)

Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 100.43 (+0.13), RVNC: 22.31 (-0.58), CLTX: 0.74 (-0.01), GSK: 46.57 (-0.67), NKTR: 10.90 (+0.16), NVS: 103.45 (-0.62)

Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 6:20PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26 Annual Piper Jaffray Healthcare Conference.
RVNC: 22.31 (-0.58)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading